Several other equities analysts have also issued reports on the stock. Guggenheim initiated coverage on shares of Cardiovascular Systems in a report on Thursday, October 17th. They set a “buy” rating and a $58.00 price objective on the stock. Zacks Investment Research raised shares of Cardiovascular Systems from a “strong sell” rating to a “hold” rating and set a $43.00 price objective on the stock in a report on Monday, January 13th. Finally, ValuEngine lowered shares of Cardiovascular Systems from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $49.60.
Shares of Cardiovascular Systems stock opened at $54.18 on Wednesday. The firm has a market cap of $1.89 billion, a price-to-earnings ratio of -541.75 and a beta of 1.62. The business has a 50-day moving average price of $47.99 and a 200-day moving average price of $46.82. The company has a quick ratio of 3.04, a current ratio of 3.45 and a debt-to-equity ratio of 0.15. Cardiovascular Systems has a twelve month low of $28.30 and a twelve month high of $54.79.
Institutional investors have recently modified their holdings of the business. Stonebridge Capital Advisors LLC purchased a new stake in shares of Cardiovascular Systems during the second quarter worth about $26,000. Exchange Traded Concepts LLC acquired a new position in shares of Cardiovascular Systems in the 4th quarter worth approximately $98,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Cardiovascular Systems by 26.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,342 shares of the medical device company’s stock worth $111,000 after acquiring an additional 495 shares during the last quarter. Harvest Investment Services LLC acquired a new position in shares of Cardiovascular Systems in the 3rd quarter worth approximately $227,000. Finally, Jefferies Group LLC acquired a new position in shares of Cardiovascular Systems in the 2nd quarter worth approximately $237,000. Institutional investors and hedge funds own 89.78% of the company’s stock.
Cardiovascular Systems Company Profile
Cardiovascular Systems, Inc, a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral, Predator 360, Stealth 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral, Diamondback 360 2.00 Peripheral, Diamondback 360 200cm Peripheral, and Diamondback 360 180cm Peripheral, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives.
Read More: How to build a Fibonacci channel
Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.